Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

BACKGROUND: Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unknown. Therefore, we conducted this retrospective cohort st...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhanhong, Zheng, Yabing, Cao, Wenming, Zhang, Yuzi, Zhao, Zhengyi, Wang, Guoqiang, Zhao, Jing, Cai, Shangli, Shao, Xiying, Huang, Jian, Ye, Weiwu, Huang, Yuan, Li, Wei, Huang, Xiang, Wu, Hao, Wang, Xiaojia, Yin, Yongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745827/
https://www.ncbi.nlm.nih.gov/pubmed/31385461
http://dx.doi.org/10.1002/cam4.2460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745827/
https://www.ncbi.nlm.nih.gov/pubmed/31385461
http://dx.doi.org/10.1002/cam4.2460

Ejemplares similares